September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Structural and functional recovery following iatrogenic macular detachment for retinal gene therapy
Author Affiliations & Notes
  • Matthew P Simunovic
    Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom
    Vitreoretinal Unit, Sydney Eye Hospital, Sydney, New South Wales, Australia
  • Jasleen Jolly
    Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom
    Oxford Eye Hospital, Oxford, United Kingdom
  • Kanmin Xue
    Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom
    Oxford Eye Hospital, Oxford, United Kingdom
  • Robert Maclaren
    Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom
    Oxford Eye Hospital, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships   Matthew Simunovic, None; Jasleen Jolly, None; Kanmin Xue, None; Robert Maclaren, NightstarX (C), NightstarX (F), University of Oxford (P)
  • Footnotes
    Support  Bayer Global Ophthalmology Awards Program, RANZCO Eye Foundation Retinal Research Fellowship
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5150. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Matthew P Simunovic, Jasleen Jolly, Kanmin Xue, Robert Maclaren; Structural and functional recovery following iatrogenic macular detachment for retinal gene therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5150.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal gene therapy necessitates iatrogenic detachment of the macula; although rhegmatogenous and exudative detachments involving this region are well-studied, little is known about the short-term effects of iatrogenic macula detachment in patients with comparatively well-preserved central vision. We therefore aimed to study the short-term recovery of structure and function following iatrogenic macula detachment performed as part of retinal gene therapy.

Methods : Five participants aged 23-71 yr, with baseline visual acuities in treated eyes ranging from 39 to 70 ETDRS letters, were recruited from a Phase I/II trial of gene therapy for choroideremia (ClinicalTrials.gov identifier NCT01461213). Subjects underwent unilateral sub-retinal injection of 0.1mL of a solution containing 1011 AAV.REP1 particles. Patients were assessed prior to surgery with follow-up at 1 day, 1 week and 1 month following surgery. Structure was assessed by spectral-domain OCT and function by visual acuity, microperimetry, color discrimination (FM 100Hue) and color matching (Rayleigh match).

Results : Resolution of sub-retinal fluid occurred by day 1 following the procedure. No evidence of change in central foveal thickness was found (change at 1 month +6.5 ± 5.8 μm vs. +19 ± 13.9 μm in treated and untreated eyes respectively). Visual acuity (change at 1 month +5.4 ± 3.3 letters and +0.8 ± 3.1 letters in treated and untreated eyes respectively) and microperimetry (-0.85 ± 3.9 dB vs. -0.7 ± 2.1 dB in treated and untreated eyes respectively) recovered to baseline by 1 month. In one subject, pseudoprotanomaly was observed at the Rayleigh match (change in log anomalquotient of > -0.2), suggesting decreased cone photopigment optical density. This finding was accompanied by a loss of tritan color discrimination at the FM100 Hue and persisted at 1 month.

Conclusions : The limited iatrogenic macular detachment performed as part of gene therapy in this study recovers by day 1 and, in contrast to macula-off rhegmatogenous detachment, does not appear to appreciably affect central foveal thickness. Whilst visual acuity and threshold sensitivity appear to recover by 1 month, subtle alterations in color matching – indicative of decreased cone photopigment optical density – may persist.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×